Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO -1.27% Cash-to-Debt is 5.09 as of Jun. 2026, which is 16% above its 10-year median of 4.40. The stock has 1 warning sign investors should review. Among 209 Medical Diagnostics & Research companies, Invitro International ranks better than 71.29% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Invitro International's cash to debt ratio for the quarter that ended in Jun. 2026 was 5.09.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Invitro Internationalcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Invitro International's Cash-to-Debt or its related term are showing as below:
IVRO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.74 Med: 4.4 Max: 5.09
Current: 5.09
During the past 9 years, Invitro International's highest Cash to Debt Ratio was 5.09. The lowest was 3.74. And the median was 4.40.
IVRO's Cash-to-Debt is ranked better than 71.29% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.07
vs IVRO: 5.09
Invitro International (OTCPK:IVRO) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Invitro International Cash-to-Debt Related Terms
Invitro International Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Invitro International's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Diagnostics & Research subindustry, Invitro International's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Invitro International's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a Cash-to-Debt of 5.09 as of Jun. 2026. This is 16% above median its historical median of 4.40. Over the past decade, Invitro International's Cash-to-Debt has ranged from 3.74 to 5.09. According to the industry distribution chart, Invitro International ranks #60 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 28.7%.
Is Invitro International's Cash-to-Debt too high?
Invitro International's current Cash-to-Debt of 5.09 is 16% above median its 10-year median of 4.40. Over the past 10 years, this metric has ranged from a low of 3.74 to a high of 5.09. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.07. Invitro International's value of 5.09 is 375.7% above this industry median. Based on the distribution chart, Invitro International ranks #60 out of 209 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Invitro International's Cash-to-Debt compare to IDTA and FUNI?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #60 out of 209 companies for Cash-to-Debt. This puts Invitro International in the upper half of its industry. The industry median Cash-to-Debt is 1.07. Invitro International's value of 5.09 is 375.7% above this benchmark. Historically, Invitro International's own Cash-to-Debt has ranged from 3.74 to 5.09 over the past decade. While the company's 10-year median is 4.40 vs. the industry median of 1.07, Invitro International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.07, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current Cash-to-Debt of 5.09 is 375.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current Cash-to-Debt is 5.09, which is 16% above median its own 10-year median of 4.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.08 — trading 30% above its estimated fair value. The current Cash-to-Debt is 5.09, which is 16% above median its 10-year median of 4.40 and 375.7% above the Medical Diagnostics & Research industry median of 1.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Invitro International (IVRO), the current Cash-to-Debt is 5.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
